BNP Paribas Financial Markets Acquires 183,191 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

BNP Paribas Financial Markets lifted its stake in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 27.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 855,951 shares of the medical instruments supplier's stock after purchasing an additional 183,191 shares during the quarter. BNP Paribas Financial Markets owned about 1.15% of OraSure Technologies worth $3,655,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. Intech Investment Management LLC purchased a new position in OraSure Technologies during the third quarter worth $84,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of OraSure Technologies by 78.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,731 shares of the medical instruments supplier's stock worth $123,000 after acquiring an additional 12,604 shares during the last quarter. Factorial Partners LLC boosted its stake in shares of OraSure Technologies by 12.0% during the 3rd quarter. Factorial Partners LLC now owns 339,953 shares of the medical instruments supplier's stock worth $1,452,000 after purchasing an additional 36,326 shares during the period. Empowered Funds LLC grew its holdings in OraSure Technologies by 22.6% during the 3rd quarter. Empowered Funds LLC now owns 359,419 shares of the medical instruments supplier's stock valued at $1,535,000 after purchasing an additional 66,210 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in OraSure Technologies by 28.1% in the 3rd quarter. Principal Financial Group Inc. now owns 66,060 shares of the medical instruments supplier's stock worth $282,000 after purchasing an additional 14,480 shares during the period. Institutional investors own 93.50% of the company's stock.

OraSure Technologies Price Performance

OSUR stock traded down $0.03 during mid-day trading on Thursday, reaching $3.84. The company had a trading volume of 979,917 shares, compared to its average volume of 890,355. The company has a market capitalization of $286.43 million, a PE ratio of 25.60 and a beta of 0.03. The firm has a 50 day moving average of $4.05 and a 200 day moving average of $4.27. OraSure Technologies, Inc. has a 12 month low of $3.72 and a 12 month high of $8.45.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $39.92 million for the quarter, compared to analysts' expectations of $38.97 million. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. OraSure Technologies's revenue was down 55.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.27 earnings per share. Analysts anticipate that OraSure Technologies, Inc. will post -0.09 EPS for the current year.

Wall Street Analyst Weigh In

OSUR has been the subject of several recent analyst reports. Evercore ISI boosted their target price on OraSure Technologies from $4.50 to $5.00 and gave the company an "in-line" rating in a research report on Wednesday, August 7th. StockNews.com upgraded OraSure Technologies from a "hold" rating to a "buy" rating in a report on Friday, October 4th.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.